• 1. Distribution characteristics of nitrogen and the related microbial community in the surface sediments of the Songhua River?
  Congyu Li,Wenfu Wang,Haiyan Wang,Guokai Yan,Weiyang Dong,Zhaosheng Chu,Huan Wang,Yang Chang RSC Adv., 2021,11, 26721-26731
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Emerging investigators series: ultraviolet and free chlorine aqueous-phase advanced oxidation process: kinetic simulations and experimental validation?
  Divya Kamath,Daisuke Minakata Environ. Sci.: Water Res. Technol., 2018,4, 1231-1238
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Hydroquinolones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolones and derivatives Hydroquinolones

Introduction to 8-(Trifluoromethyl)quinolin-2(1H)-one (CAS No. 920494-30-0)

8-(Trifluoromethyl)quinolin-2(1H)-one, identified by its CAS number 920494-30-0, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic organic compound features a quinoline core substituted with a trifluoromethyl group at the 8-position and a carbonyl group at the 2-position, making it a versatile scaffold for the development of novel bioactive molecules.

The< strong>trifluoromethyl group is a well-documented pharmacophore that enhances the metabolic stability, lipophilicity, and binding affinity of drug candidates. Its introduction into molecular structures often leads to improved pharmacokinetic profiles, which are crucial for the efficacy and safety of therapeutic agents. In the context of quinolinone derivatives, the presence of this group has been associated with enhanced activity against various biological targets, including enzymes and receptors involved in cancer, inflammation, and infectious diseases.

Recent advancements in synthetic methodologies have enabled more efficient and scalable production of 8-(Trifluoromethyl)quinolin-2(1H)-one, facilitating its exploration in drug discovery programs. The compound’s structural framework allows for further functionalization, enabling the creation of libraries of derivatives with tailored properties. This flexibility has made it a valuable intermediate in the synthesis of potential therapeutic agents targeting complex diseases.

In oncology research, quinolinone derivatives have garnered considerable attention due to their demonstrated efficacy against multiple types of cancer. The trifluoromethyl-substituted quinolinones are particularly intriguing because they can modulate key signaling pathways involved in tumor growth and progression. Preclinical studies have highlighted their potential as inhibitors of kinases and other enzymes that play critical roles in cancer cell proliferation and survival. For instance, derivatives of 8-(Trifluoromethyl)quinolin-2(1H)-one have shown promise in disrupting the activity of tyrosine kinases, which are often overexpressed in cancer cells.

Beyond oncology, this compound has been investigated for its antimicrobial properties. The structural features of quinolinones contribute to their ability to interact with bacterial enzymes and inhibit essential metabolic processes. The incorporation of a trifluoromethyl group further enhances their efficacy by improving binding affinity to target proteins. Preliminary studies have demonstrated that certain derivatives exhibit potent activity against Gram-positive and Gram-negative bacteria, as well as fungi. This makes them attractive candidates for developing novel antibiotics to combat resistant strains.

The pharmacological profile of 8-(Trifluoromethyl)quinolin-2(1H)-one is also relevant in the treatment of inflammatory diseases. Quinolinone derivatives have been shown to modulate inflammatory pathways by inhibiting key mediators such as cyclooxygenase (COX) and lipoxygenase (LOX). The presence of the trifluoromethyl group can enhance their anti-inflammatory effects by improving their interaction with these enzymes. Clinical trials and preclinical studies have suggested that such compounds may offer therapeutic benefits in conditions like rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory disorders.

The synthesis of 8-(Trifluoromethyl)quinolin-2(1H)-one involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Modern synthetic strategies often employ transition metal catalysis to achieve high yields and selectivity. Palladium-catalyzed cross-coupling reactions are particularly useful for constructing the quinoline core, while fluorination techniques are employed to introduce the trifluoromethyl group. These advances in synthetic chemistry have not only simplified the production process but also opened new avenues for structural diversification.

The computational modeling and molecular docking studies have played a pivotal role in understanding the interactions between 8-(Trifluoromethyl)quinolin-2(1H)-one and its biological targets. These studies provide insights into binding affinities, enzyme inhibition kinetics, and potential side effects. By leveraging computational tools, researchers can optimize the compound’s structure to enhance its therapeutic index while minimizing toxicity. This approach has accelerated the discovery process by allowing rapid screening of large libraries of derivatives.

In conclusion, 8-(Trifluoromethyl)quinolin-2(1H)-one (CAS No. 920494-30-0) represents a promising scaffold for pharmaceutical development. Its unique structural features, combined with the versatility of synthetic methodologies, make it an attractive candidate for further exploration in drug discovery. The compound’s potential applications in oncology, antimicrobial therapy, and anti-inflammatory treatments highlight its significance in modern medicinal chemistry. As research continues to uncover new biological activities and synthetic strategies, 8-(Trifluoromethyl)quinolin-2(1H)-one is poised to contribute significantly to the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)